{"title":"Interferon in Liver Diseases: Recent Advances.","authors":"Yuting Gao, Yuhang Yin, Pengpeng Xie, Deyu Zhang, Hongyu Li, Xingshun Qi","doi":"10.1007/s12325-025-03291-8","DOIUrl":null,"url":null,"abstract":"<p><p>Interferons (IFNs) are a pivotal class of cytokines with multifaceted roles in antiviral defense, immune regulation, and antitumor activity. Structural and functional distinctions among IFN types (I, II, and III) underlie their diverse biological effects. IFN production is initiated by pattern recognition receptor signaling, containing Toll-like receptors, RIG-I-like receptors, and the cGAS-STING axis, which activates downstream pathways, such as JAK-STAT, PI3K-AKT, NF-κB, and MAPK signaling pathways. These pathways critically influence the pathogenesis, progression, therapeutic management, and prognosis of liver diseases. This review delineates the mechanistic roles of IFN-associated signaling in viral hepatitis, non-alcoholic fatty liver disease, alcohol-associated liver disease, liver fibrosis, and hepatocellular carcinoma. We further elucidate IFN-mediated regulatory networks in viral defense, metabolic dysregulation, immune responses, and inflammatory activation. By integrating these insights, the review provides a novel therapeutic direction to unravel context-specific IFN dynamics and address unmet needs in the management of liver diseases, thereby fostering personalized approaches to improve clinical outcomes.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03291-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Interferons (IFNs) are a pivotal class of cytokines with multifaceted roles in antiviral defense, immune regulation, and antitumor activity. Structural and functional distinctions among IFN types (I, II, and III) underlie their diverse biological effects. IFN production is initiated by pattern recognition receptor signaling, containing Toll-like receptors, RIG-I-like receptors, and the cGAS-STING axis, which activates downstream pathways, such as JAK-STAT, PI3K-AKT, NF-κB, and MAPK signaling pathways. These pathways critically influence the pathogenesis, progression, therapeutic management, and prognosis of liver diseases. This review delineates the mechanistic roles of IFN-associated signaling in viral hepatitis, non-alcoholic fatty liver disease, alcohol-associated liver disease, liver fibrosis, and hepatocellular carcinoma. We further elucidate IFN-mediated regulatory networks in viral defense, metabolic dysregulation, immune responses, and inflammatory activation. By integrating these insights, the review provides a novel therapeutic direction to unravel context-specific IFN dynamics and address unmet needs in the management of liver diseases, thereby fostering personalized approaches to improve clinical outcomes.
期刊介绍:
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.